Canaccord Genuity Group Reiterates Hold Rating for Pliant Therapeutics (NASDAQ:PLRX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports. They currently have a $4.00 price target on the stock, down from their previous price target of $43.00. Canaccord Genuity Group’s price objective would indicate […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports. They currently have a $4.00 price target on the stock, down from their previous price target of $43.00. Canaccord Genuity Group’s price objective would indicate […]
